These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 16278269

  • 21. Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency.
    Chakhtoura Z, Bachelot A, Samara-Boustani D, Ruiz JC, Donadille B, Dulon J, Christin-Maître S, Bouvattier C, Raux-Demay MC, Bouchard P, Carel JC, Leger J, Kuttenn F, Polak M, Touraine P, Centre des Maladies Endocriniennes Rares de la Croissance and Association Surrénales.
    Eur J Endocrinol; 2008 Jun; 158(6):879-87. PubMed ID: 18390993
    [Abstract] [Full Text] [Related]

  • 22. Effects of androgen excess and glucocorticoid exposure on bone health in adult patients with 21-hydroxylase deficiency.
    Auer MK, Paizoni L, Hofbauer LC, Rauner M, Chen Y, Schmidt H, Huebner A, Bidlingmaier M, Reisch N.
    J Steroid Biochem Mol Biol; 2020 Nov; 204():105734. PubMed ID: 32784048
    [Abstract] [Full Text] [Related]

  • 23. Bone mineral density in prepubertal and in adolescent and young adult patients with the salt-wasting form of congenital adrenal hyperplasia.
    Gussinyé M, Carrascosa A, Potau N, Enrubia M, Vicens-Calvet E, Ibáñez L, Yeste D.
    Pediatrics; 1997 Oct; 100(4):671-4. PubMed ID: 9310523
    [Abstract] [Full Text] [Related]

  • 24. Reduction in daily hydrocortisone dose improves bone health in primary adrenal insufficiency.
    Schulz J, Frey KR, Cooper MS, Zopf K, Ventz M, Diederich S, Quinkler M.
    Eur J Endocrinol; 2016 Apr; 174(4):531-8. PubMed ID: 26811406
    [Abstract] [Full Text] [Related]

  • 25. Bone mineral density in young adult women with congenital adrenal hyperplasia.
    Raizada N, Jyotsna VP, Upadhyay AD, Gupta N.
    Indian J Endocrinol Metab; 2016 Apr; 20(1):62-6. PubMed ID: 26904470
    [Abstract] [Full Text] [Related]

  • 26. Sexual difference in bone geometry of adult patients with classical congenital adrenal hyperplasia: data using peripheral quantitative computed tomography.
    Bechtold S, Beyerlein A, Bonfig W, Dalla Pozza R, Putzker S, Otto R, Schmidt H, Schwarz HP.
    Horm Res Paediatr; 2014 Apr; 82(3):171-8. PubMed ID: 25171196
    [Abstract] [Full Text] [Related]

  • 27. The effect of glucocorticoid replacement therapy on bone mineral density in children with congenital adrenal hyperplasia.
    Cetinkaya S, Kara C.
    J Pediatr Endocrinol Metab; 2011 Apr; 24(5-6):265-9. PubMed ID: 21823521
    [Abstract] [Full Text] [Related]

  • 28. [Estimation of influence of congenital-adrenal hyperplasia treatment on bone mineralisation evaluated with densitometry].
    Romanowska H, Krzywińska-Zdeb E, Giżewska M, Kotkowiak L, Safranow K, Horodnicka-Józwa A, Petriczko E, Krupa B, Walczak M.
    Pediatr Endocrinol Diabetes Metab; 2012 Apr; 18(1):21-6. PubMed ID: 22525687
    [Abstract] [Full Text] [Related]

  • 29. Use of an aromatase inhibitor in children with congenital adrenal hyperplasia: Impact of anastrozole on bone mineral density and visceral adipose tissue.
    Halper A, Sanchez B, Hodges JS, Dengel DR, Petryk A, Sarafoglou K.
    Clin Endocrinol (Oxf); 2019 Jul; 91(1):124-130. PubMed ID: 31070802
    [Abstract] [Full Text] [Related]

  • 30. Quantitative computed tomography of the lumbar spine, not dual x-ray absorptiometry, is an independent predictor of prevalent vertebral fractures in postmenopausal women with osteopenia receiving long-term glucocorticoid and hormone-replacement therapy.
    Rehman Q, Lang T, Modin G, Lane NE.
    Arthritis Rheum; 2002 May; 46(5):1292-7. PubMed ID: 12115236
    [Abstract] [Full Text] [Related]

  • 31. Gonadotropin-Releasing Hormone Agonist Therapy and Longitudinal Bone Mineral Density in Congenital Adrenal Hyperplasia.
    Flokas ME, Wakim P, Kollender S, Sinaii N, Merke DP.
    J Clin Endocrinol Metab; 2024 Jan 18; 109(2):498-504. PubMed ID: 37643900
    [Abstract] [Full Text] [Related]

  • 32. Bone mineral density and body composition in children with congenital adrenal hyperplasia.
    Halper A, Sanchez B, Hodges JS, Kelly AS, Dengel D, Nathan BM, Petryk A, Sarafoglou K.
    Clin Endocrinol (Oxf); 2018 Jun 18; 88(6):813-819. PubMed ID: 29460378
    [Abstract] [Full Text] [Related]

  • 33. BclI polymorphism of the glucocorticoid receptor gene is associated with increased bone resorption in patients on glucocorticoid replacement therapy.
    Koetz KR, van Rossum EF, Ventz M, Diederich S, Quinkler M.
    Clin Endocrinol (Oxf); 2013 Jun 18; 78(6):831-7. PubMed ID: 23134110
    [Abstract] [Full Text] [Related]

  • 34. Normal bone health in young adults with 21-hydroxylase enzyme deficiency undergoing glucocorticoid replacement therapy.
    Borges JH, de Oliveira DM, de Lemos-Marini SHV, Geloneze B, Guerra-Júnior G, Gonçalves EM.
    Osteoporos Int; 2022 Jan 18; 33(1):283-291. PubMed ID: 34406442
    [Abstract] [Full Text] [Related]

  • 35. Bone Mineral Content and Density in Indian Children with Congenital Adrenal Hyperplasia.
    Ganesh R, Suresh N, Janakiraman L.
    Indian Pediatr; 2018 Oct 15; 55(10):880-882. PubMed ID: 29941696
    [Abstract] [Full Text] [Related]

  • 36. Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
    Völkl TM, Simm D, Beier C, Dörr HG.
    Pediatrics; 2006 Jan 15; 117(1):e98-105. PubMed ID: 16396852
    [Abstract] [Full Text] [Related]

  • 37. Height, bone mineral density and bone markers in congenital adrenal hyperplasia.
    Paganini C, Radetti G, Livieri C, Braga V, Migliavacca D, Adami S.
    Horm Res; 2000 Jan 15; 54(4):164-8. PubMed ID: 11416232
    [Abstract] [Full Text] [Related]

  • 38. Bone mineral density and bone turnover in asthmatics treated with long-term inhaled or oral glucocorticoids.
    Ebeling PR, Erbas B, Hopper JL, Wark JD, Rubinfeld AR.
    J Bone Miner Res; 1998 Aug 15; 13(8):1283-9. PubMed ID: 9718197
    [Abstract] [Full Text] [Related]

  • 39. The relationship between serum dehydroepiandrosterone sulfate concentration and bone mineral density, lipids, and hormone replacement therapy in premenopausal and postmenopausal women.
    Osmanagaoglu MA, Okumuş B, Osmanagaoglu T, Bozkaya H.
    J Womens Health (Larchmt); 2004 Nov 15; 13(9):993-9. PubMed ID: 15665656
    [Abstract] [Full Text] [Related]

  • 40. Hormone predictors of bone mineral density changes during the menopausal transition.
    Sowers MR, Jannausch M, McConnell D, Little R, Greendale GA, Finkelstein JS, Neer RM, Johnston J, Ettinger B.
    J Clin Endocrinol Metab; 2006 Apr 15; 91(4):1261-7. PubMed ID: 16403818
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.